These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28738707)

  • 1. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Press KR; Uy N; Keefer J; Gore SD; Carraway HE; Sakoian S; Prebet T
    Leuk Lymphoma; 2018 Mar; 59(3):755-757. PubMed ID: 28738707
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
    Prebet T; Sun Z; Figueroa ME; Ketterling R; Melnick A; Greenberg PL; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Litzow M; Gabrilove J; Erba HP; Gore SD; Tallman MS
    J Clin Oncol; 2014 Apr; 32(12):1242-8. PubMed ID: 24663049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
    Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Navada SC; Garcia-Manero G; OdchimarReissig R; Pemmaraju N; Alvarado Y; Ohanian MN; John RB; Demakos EP; Zbyszewski PS; Maniar M; Woodman RC; Fruchtman SM; Silverman LR
    Leuk Res; 2020 Jul; 94():106369. PubMed ID: 32442785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
    Yang H; Fang Z; Wei Y; Hu Y; Calin GA; Kantarjian HM; Garcia-Manero G
    Am J Hematol; 2011 Feb; 86(2):237-8. PubMed ID: 21264920
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
    Platzbecker U; Germing U
    Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
    Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
    Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
    Duncavage EJ; Uy GL; Petti AA; Miller CA; Lee YS; Tandon B; Gao F; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Jacoby MA; Cashen AF; Wartman LD; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ; Welch JS
    Blood; 2017 Mar; 129(10):1397-1401. PubMed ID: 28082444
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia.
    de Witte T; Hermans J; van Biezen A; Vernant J; Kolb H; Zwaan F; Vossen J; Lönnqvist B; Beelen D; Ferrant A
    Bone Marrow Transplant; 1991; 7 Suppl 2():40. PubMed ID: 1878713
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Maslah N; Diawara Y; Sebert M; Giraudier S; Fenaux P; Cassinat B
    Br J Haematol; 2021 Aug; 194(4):e77-e79. PubMed ID: 34145569
    [No Abstract]   [Full Text] [Related]  

  • 15. [The comparison of short-term efficacies between decitabine and HA regimen for MDS/AML patients].
    Chen WF; Huang F; Zha J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):143-4. PubMed ID: 22730671
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
    Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
    Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.
    Stomper J; Ihorst G; Suciu S; Sander PN; Becker H; Wijermans PW; Plass C; Weichenhan D; Bissé E; Claus R; Lübbert M
    Haematologica; 2019 Jan; 104(1):59-69. PubMed ID: 30171030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.